Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.
about
Immunological Landscape and Clinical Management of Rectal CancerCombination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy.Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapySerum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model.Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age.P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy.Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancerCMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis.YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional studyIdentification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancerPredicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation.A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patientsAn update on preoperative radiotherapy for locally advanced rectal cancer.An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancerCombined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy.Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours.Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence.Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapyMeta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases.Radiotherapy response in microsatellite instability related rectal cancerPredictive markers of radiotherapy-induced rectal cancer regression.Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study.Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.Response of glutathione S-transferase Pi (GSTP1) to neoadjuvant therapy in rectal adenocarcinoma.Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo.Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation.Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.Rectal cancer: assessment of response to neoadjuvant chemoradiation by dynamic contrast-enhanced MRI.Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy.Molecular changes consistent with increased proliferation and invasion are common in rectal cancer.miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy.The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy.MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer.
P2860
Q26768531-E0FA2B2C-DA0F-45E5-9E72-B1106B971C27Q31095551-E8B8B137-4FE8-4B1E-AD49-DB57C2F9ACA2Q33320579-1EA61E61-5283-477C-AAAE-764C568A6F6AQ33764534-B5856901-DCCD-44B6-9B7A-B1BF313A7B4AQ33799243-DFD5DC78-DF6F-4875-A30D-ED30F7C8D98DQ34438092-065A7BDD-C136-4E67-BFEA-19631FF829EDQ34552155-AEAEF14D-1FA0-493D-9CA4-F7E10F1E6040Q35100017-E8274204-6F02-4A38-BB78-22A58AC37DC2Q35106489-48A19FF8-3CD3-4A9B-9CFE-07CE0ED646FAQ35433475-E38602F6-C7CC-4F5C-997C-75F5E2BA363AQ35460703-0CB17E87-30A9-4754-A2CB-A518D61751B8Q36022348-1A2A41DF-D481-4F0B-9E54-1D3ADE0E9BFCQ36211293-E8FCA509-3C56-43D6-91CA-B9F469BAC37BQ36229969-3FCBEE1A-1432-4B33-BE95-695B988687B4Q36544900-FB7CB1B0-B97D-4F81-8927-F8B7DD590724Q36614764-1793C273-996B-490B-BF95-9F5CEB8C208AQ37132742-DF1D4834-4620-46DD-B013-6F3BE7988475Q37156639-1958DC61-108A-44C1-A1BA-67800717C58EQ37298667-C0B337AC-8CDD-41EA-9805-D633850AEA32Q37321935-7DB911FD-9112-4B24-9CB0-C9BB98224C23Q37398630-B1D2A780-45F7-44EA-9201-27F0E600280CQ37562470-AFB83481-EA84-4225-88CE-718E6223008EQ37977032-F3197C9E-BECF-4340-9D16-36BCC744D31CQ38088639-DA82AFE5-A500-4BFF-B21D-54843A32F005Q38239477-9D4D3BE6-938A-452D-83B5-1CBA7C004EF2Q38489314-868B652F-3A92-4ED4-849B-CDC4C26EEC1EQ38623990-2768EB40-98FA-4269-9C4C-78E66C45569AQ39644875-CA55EAB2-6032-4A09-AB16-3004092C94BBQ39687832-9632A388-128A-4E29-AE83-45A93016F8FFQ41858808-5AEA5297-3337-4B90-B1AE-790F8AC011BFQ42669180-FE4117E9-6CC3-446D-8949-A036744B20ADQ43053804-D98484E4-64A4-4C4B-B5B0-9C74C1521CCAQ43554577-69974596-3192-410A-B181-590D67F8BC67Q45001727-590FC686-1A8B-4EF5-84F4-E6781491E1D9Q45120532-7CB061CF-75D5-41DF-8F31-FF0E51C94711Q46294728-D939C44F-CEE0-4676-BBFA-69E7A469FC75Q48283608-96B56D8F-0FAC-4307-B87C-38DC0EBD2BD0Q49219370-31FDBB06-3908-4CF5-9E62-BBADAFDDEBD9Q53273843-DBF441E2-FDA9-4BEC-B7A4-527D42C09427Q53515189-89E10E0D-8937-454F-9908-5B9666C17A40
P2860
Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pathological and molecular pre ...... neoadjuvant radiochemotherapy.
@ast
Pathological and molecular pre ...... neoadjuvant radiochemotherapy.
@en
type
label
Pathological and molecular pre ...... neoadjuvant radiochemotherapy.
@ast
Pathological and molecular pre ...... neoadjuvant radiochemotherapy.
@en
prefLabel
Pathological and molecular pre ...... neoadjuvant radiochemotherapy.
@ast
Pathological and molecular pre ...... neoadjuvant radiochemotherapy.
@en
P2093
P1476
Pathological and molecular pre ...... neoadjuvant radiochemotherapy.
@en
P2093
P356
10.1016/J.EJSO.2005.09.010
P577
2005-12-01T00:00:00Z